期刊文献+

缬沙坦对豚鼠心房肌细胞电生理的影响

Effects of valsartan on electrophysiology of guinea pig atrial myocytes
下载PDF
导出
摘要 目的从心肌细胞电生理的角度探讨血管紧张素Ⅱ受体阻断药(ARB)类药物抗房颤的可能机制。方法采用全细胞膜片钳技术的电流钳方法记录单细胞动作电位,采用全细胞膜片钳技术的电压钳方法记录心房肌细胞的延迟整流钾电流(Ik)。观察ARB类药物缬沙坦对豚鼠心房肌细胞动作电位及离子通道电流的影响。结果缬沙坦100μM可延长心房肌细胞动作电位时程,尤其是蛾从(52.2±6.5)ms延长至(58.6±7.8ms,P〈0.01),APD90从(94.0±11.7)ms延长至(105.3±14.0ms,P〈0.01),而对RMP、APA无显著影响。缬沙坦100μM明显抑制心房肌细胞IK的峰值电流,从5.33±0.13(pA/pF)减小至4.49±0.48(pA/pF)(P〈0.05),并呈电压依赖性。结论高浓度缬沙坦延长心房肌细胞动作电位时程、APD50及APD50。缬沙坦抑制心房肌细胞延迟外向钾电流,可能是引起其动作电位时程延长的一个重要因素。缬沙坦延长心房肌动作电位时程,可能在房颤的转复及房颤转复后窦性心律的维持中有价值。 Objective To study the potential mechanism of angiotensin Ⅱ blocker(ARB)on atrial fibrillation from cellular electrophysiology of myocytes. Methods Whole - cell patch clamp technique was adopted. Current- clamp mode was used to record single cell action potential. The effect of ARB on action potential of guinea pig atrial myocytes were investigated. Patch - clamp mode was used to record delayed rectifier K^+ currents (Ik). Results V alsartan 100 μM lengthened atrial myocyte action potential duration, especially APD50 from (52.2 ±6.5) ms to (58.6±7.8) ms( P 〈0.01)and APDgO from (94.0± 11.7) ms to (105.3 ± 14.0) ms( P 〈 0.01) ,but had no effect on RMP and APA. Valsartan 100 μm reduced atrial myocytes peak Ik current from 5.33 ± 0.13( pA/pF) to 4.49 ± 0.48(pA/pF) ,voltage dependently. Conclusions At high concentration, valsaxtan increases APD of atrial myocytes of guinea pig without changing APA and RMP. Inhibiting Ik by valsartan is an important factor contributing to the prolongation of APD. By prolonging APD, valsartan may have potential in converting AF to sinus rhythm or in maintaining sinus rhythm after successful convertion.
出处 《武警医学》 CAS 2008年第10期898-900,共3页 Medical Journal of the Chinese People's Armed Police Force
关键词 缬沙坦 动作电位 离子通道电流 心房肌 Valsattan Action potential duration Ion channel currents Atrial myocytes
  • 相关文献

参考文献7

  • 1Wachtell K, Lehto M, Gerdts E et al . Angiotensin Ⅱ Receptor Blockade Reduces New - Onset Atrial Fibrillation and Subsequent Stroke Compared to Atenolol: The Eosartan Intervention for End Point Reduction In Hypertension (LIFE) Study.J Am Coll Cardiol,2005,45(5) :712
  • 2Madrid AH, Marin IM, Cervantes CE et al . Prevention of recurrences in patients with lone areal fibrillation. The dose - dependent effect of ang4otensin Ⅱ receptor blocker. J Renin Angiotensin Aldosterone System, 2004,5 (3) : 114
  • 3Ducharme A, Swedberg K, Pfeffer MA et al . Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and mobidity(CHARM) program. Am Heart J,2006,151(1) :985
  • 4刘晓惠,杜昕.血管紧张素Ⅱ与心房颤动[J].中国医刊,2005,40(8):7-9. 被引量:8
  • 5Kalus JS, BCPS D, Coleman CI et al. The Impact of Suppressing the Renin - Angiotensin System on Atrial Fibrillation,J Clin Pharmacdogy,2006,46(21) :21
  • 6Maggioni AP, Latini R, Carson PE et al . Valsartan reduces the incidence of Atrial fibrillation in patients with heart failure (Val - HeFT) .Am Heart J,2005,149(3) :548
  • 7Nattel S. Atrial Electrophysiology and Mechanisms of Atrial Fibrillation, J Cordiovasc Pharmacol Therapeut, 2003,8 (1) : S5

二级参考文献22

  • 1Madrid AH, Matin IM, Cervantes CE, et all Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers [ J ]. J Renin Angiotensin Aldosterone Syst, 2004, 5:114- 120.
  • 2Madrid AH, Peng J, Zamora J,et al. The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases : meta-analysis of randomized controlled clinical trials [ J ]. Pacing Clin Electrophysial, 2004, 27 :1405 - 1410.
  • 3Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications [ J ]. Arch Intern Med , 1995, 155:469 - 473.
  • 4Ruigomez A, Jollan-sson S, Wallander MA, et al. Incidenceof chronic atrial fibrillation in general practice and its treatment pattern [ J ]. J Clin Epidemiol, 2002, 55: 358- 363.
  • 5Go AS: Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study[ J]. JAMA, 2001, 285:2370 - 2375.
  • 6Kannel WB, Abbott RD,Savage DD, et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med ,1982, 306:1018 - 1022.
  • 7Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham heart study[J]. JAMA, 1994, 271:840 - 844.
  • 8Kato'T,-Yamashita T, Sagara K, et al. Progressive nature of paroxysmal atrial fibrillation. Observations from a 14-year follow-up study[J]. Circ J, 200d, 68:568-572.
  • 9Wyse D, GandGersh BJ. Atrial fibrillation : a perspective thinking inside and outside the box [ J ]. Circulation, 2004, 109:3089 -3095.
  • 10Cha TJ, Ehrlich JR, Zhang L, et al. Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure [ J ]. Circulation, 2004, 109 :412 -418.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部